BACE1 as a potential biomarker for alzheimer's disease

Journal of Alzheimer's Disease

Volumn 24, Issue SUPPL. 2, 2011, Pages 53-59

  Decourt, Boris ^a   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; BACE1; biomarker; blood; brain; cerebrospinal fluid; secretase

Indexed keywords

BETA SECRETASE 1; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BRAIN; BRAIN LEVEL; CEREBROSPINAL FLUID; DEMENTIA; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; IMMUNODETECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; REVIEW;

EID: 79955650985     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-110017     Document Type: Review

References (54)

1. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: acomplexbut coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
2. Humpel C (2011) Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 29, 26-32.
3. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
4. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cere-brospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
5. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537.
6. Brouwers N, Sleegers K, Van Broeckhoven C (2008) Molec-ular genetics of Alzheimer's disease: an update. Ann Med 40, 562-583.
7. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chap-man C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14, 419-427. (Pubitemid 30026585)
8. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomen-saari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537-540.
9. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic pro-tease BACE. Science 286, 735-741.
10. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gur-ney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537.
11. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B (2005) Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 280, 30797-30806. (Pubitemid 41291810)
12. Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 324, 957-969. (Pubitemid 351397853)
13. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synap-tic pathology in APP transgenic mice. J Biol Chem 282, 26326-26334. (Pubitemid 47443774)
14. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phe-notype and abolished beta-amyloid generation. Nat Neurosci 4, 231-232. (Pubitemid 32194866)
15. Haque A, Banik NL, Ray SK (2008) New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer's disease: cathepsin inhibitors as potential ther-apeutics. CNS Neurol Disord Drug Targets 7, 270-277.
16. Murayama KS, Kametani F, Araki W (2005) Extracellular release of BACE1 holoproteins from human neuronal cells. Biochem Biophys Res Commun 338, 800-807. (Pubitemid 41597714)
17. Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, Bouwman F, Lindeman J, Bollen EL, Hanemaaijer R (2006) Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem52, 1168-1174. (Pubitemid 43794431)
18. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y (2007) Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of riskin mild cognitive impairment. Arch Gen Psychiatry 64, 718-726. (Pubitemid 46878672)
19. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9, 3-4. (Pubitemid 36098241)
20. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP (2010) BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem 112, 1045-1053.
21. Andrau D, Dumanchin-Njock C, Ayral E, Vizzavona J, Farzan M, Boisbrun M, Fulcrand P, Hernandez JF, Martinez J, Lefranc-Jullien S, Checler F (2003) BACE1-and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel flu-orimetric assay, and identification of new in vitro inhibitors. J Biol Chem 278, 25859-25866. (Pubitemid 36835346)
22. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. JBiol Chem 277, 4687-4693. (Pubitemid 34968499)
23. Johnston JA, Liu WW, Coulson DT, Todd S, Murphy S, Brennan S, Foy CJ, Craig D, Irvine GB, Passmore AP (2008) Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol Aging 29, 661-668. (Pubitemid 351400819)
24. Hayley M, Perspicace S, Schulthess T, Seelig J (2009) Cal-cium enhances the proteolytic activity of BACE1: An in vitro biophysical and biochemical characterization of the BACE1-calcium interaction. Biochim Biophys Acta 1788, 1933-1938.
25. Klaver DW, Wilce MC, Cui H, Hung AC, Gasperini R, Foa L, Small DH (2010) Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Biol Chem 391, 849-859.
26. Silvestri R (2009) Boom in the development of non-pep-tidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev 29, 295-338.
27. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neo-cortex in Alzheimer disease. Arch Neurol 59, 1381-1389. (Pubitemid 35014802)
28. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51, 783-786. (Pubitemid 34568861)
29. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC (2004) Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164, 719-725. (Pubitemid 38364685)
30. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. Neuro Rx 1, 226-234. (Pubitemid 46591884)
31. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y (2007) Deletion of tumor necro-sis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178, 829-841. (Pubitemid 47347367)
32. Okonkwo OC, Alosco ML, Jerskey BA, Sweet LH, Ott BR, Tremont G (2010) Cerebral atrophy, apolipoprotein E varep-silon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment. Alzheimers Dement 6, 404-411.
33. Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G (2004) Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol 55, 898-899. (Pubitemid 38702591)
34. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, King E, Devanarayan V, Cook JJ, Simon AJ (2008) Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin Biochem 41, 986-996.
35. Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ (2006) CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology 67, 710-712. (Pubitemid 44273629)
36. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clear-ance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNSNeurol Disord Drug Targets 8, 16-30.
37. Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, Fagan AM, Mehta PD, Hyman BT, Selkoe DJ, Grodstein F (2009) Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis 16, 277-285.
38. Oh ES, Troncoso JC, Fangmark Tucker SM (2008) Maxi-mizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med 10, 195-207.
39. Satoh J, Kuroda Y (2000) Amyloid precursor protein beta-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology 20, 289-296. (Pubitemid 32125545)
40. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF (2003) Transcriptprofiling ofhumanplatelets using microarray and serial analysis of gene expression. Blood 101, 2285-2293. (Pubitemid 36302071)
41. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P, et al. (1990) The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 265, 15977-15983.
42. Li QX, Berndt MC, Bush AI, Rumble B, Mackenzie I, Friedhuber A, Beyreuther K, Masters CL (1994) Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 84, 133-142.
43. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 74, 386-392. (Pubitemid 37362815)
44. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213, 96-103.
45. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A (2010) Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 45, 53-56.
46. Tang K, Hynan LS, Baskin F, Rosenberg RN (2006) Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci 240, 53-58. (Pubitemid 41814953)
47. Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C (2010) Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J Cereb Blood Flow Metab 30, 1817-1820.
48. Colciaghi F, Marcello E, Borroni B, Zimmermann M, Calta-girone C, Cattabeni F, Padovani A, Di Luca M (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62, 498-501. (Pubitemid 38200872)
49. Liu WW, Todd S, Coulson DT, Irvine GB, Passmore AP, McGuinness B, McConville M, Craig D, Johnston JA (2009) A novel reciprocal and biphasic relationship between mem-brane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets. J Neurochem 108, 341-349.
50. Sixma JJ, van den Berg A, Hasilik A, von Figura K, Geuze HJ (1985) Immuno-electron microscopical demonstration of lysosomes in human blood platelets and megakaryocytes using anti-cathepsin D. Blood 65, 1287-1291. (Pubitemid 15121956)
51. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC (2008) Alteration ofBACE1-dependentNRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci US A 105, 5585-5590. (Pubitemid 351753906)
52. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) BACE1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9, 1520-1525. (Pubitemid 44862660)
53. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman PE, Zehntner SP, Skovronsky DM (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
54. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M (2010) The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6, 202-211, e207.